Tinengotinib (TT-00420), a Novel Spectrum-Selective Small Molecule Kinase Inhibitor, Is Highly Active Against Triple Negative Breast Cancer

Exposure to tinengotinib specifically inhibited proliferation across all subtypes of TNBC in vitro and in vivo, while leaving luminal breast cancer cells intact. Incubation of HCC1806 with tinengotinib led to dose-dependent down-regulation of genes essential for TNBC cell growth and proliferation.